Trials / Recruiting
RecruitingNCT06854042
A Study of Oral E1018 in Healthy Adult Participants
A First-In-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral E1018 in Healthy Adult Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of the study is to evaluate the safety and tolerability of single ascending oral doses of E1018 in healthy adult participants and to evaluate the pharmacokinetics (PK) of E1018 in plasma and urine after single oral dose administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E1018 | Specified dose on specified days. |
| DRUG | Placebo | E1018 matching placebo on specified days. |
Timeline
- Start date
- 2025-02-26
- Primary completion
- 2025-12-23
- Completion
- 2025-12-23
- First posted
- 2025-03-03
- Last updated
- 2025-09-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06854042. Inclusion in this directory is not an endorsement.